Bleeding Disorder Prescriber Order Form				
Patient name: Date of birth:				
Address:		•		
Phone:	Height:	□ inches	□ cm Weight:	□ lbs □ kg
	Clinical Info	ormation		
Primary Diagnosis Description:			ICD-10 Code:	
Severity: □ Severe □ Moderate □ Mild □ Type 1 □ Type 2 □ Type 3				
IV access device: Nursing required: ☐ Yes ☐ No				
Additional information:				
	Factor Product	Prescription		
Factor Product: Dosing Regimer		,		
Select One: Prophylaxis Episodic Peri-operative				
Additional dosing instructions:				
Refill as directed □ x6 months □ x12 months □ times				
Actual factor replacement product dose may be within (+/-10%) than the target dose specified.				
Ancillary Orders				
IV Flush Orders				
☐ Peripheral: 0.9% Sodium Chloride 2 to 3 mL pre-/post-use. Heparin (10 unit/mL) 1 to 3 mL post-use.				
☐ For Maintenance <i>(select one):</i> ☐ 0.9% Sodium Chloride 2 to 3 mL every 12 hr <i>or</i> ☐ Heparin (10 unit/mL) 1 to 3 mL every 24 hr.				
If infusing via Peripheral IV, skilled nurse to insert.				
☐ Peripheral-Midline: 0.9% Sodium Chloride NS 3 to 5 mL pre-/post-use, 5 mL pre-lab draw, and 10 mL post-lab draw.				
Heparin (10 unit/mL) 3 mL post-use.				
\square For Maintenance <i>(select one):</i> Heparin \square (10 unit/mL) 3 mL every 12 hr or \square (100 unit/mL) 3 mL every 24 hr.				
If infusing via Peripheral IV, skilled nurse to insert.				
☐ PICC and Central Tunneled/Non-Tunneled: NS 5 mL pre-/post-use, 5 mL pre-lab draw, and 10 mL post-lab draw.				
(Select one): Heparin \Box (10 unit/mL) 5 mL or \Box (100 unit/mL) post-use.				
☐ For Maintenance (select one): Heparin ☐ (10 unit/mL) 5 mL or ☐ (100 unit/mL) 3 mL every 24 hr.				
☐ Implanted Port: 0.9% Sodium Chloride 5 to 10 mL pre-/post-use and 10 to 20 mL pre-/post-lab draw.				
Heparin (100 unit/mL) 3 to 5 mL post-use.				
For Maintenance, Heparin (100 unit/mL) 3 to 5 mL every 24 hr if accessed, or weekly to monthly if not accessed.				
Nurse to access implanted port.				
☐ Valved Catheters: 0.9% Sodium Chloride 5 to 10 mL pre-/post-use and 10 to 20 mL pre-/post-lab draw. For maintenance, 0.9% Sodium Chloride 5 to 10 mL at least weekly.				
·				
\square Apply 30 $-$ 60 minutes prior to access: \square EMLA cream, 30g tube \square LMX cream, 30g tube Refill above ancillary orders as directed x1 year.				
I certify that the use of the indicated treat.	ment is medically n	ecessary, and I wil	l be supervising the patient	's treatment.
,,	,	,,		
Prescriber Signature:	D		Date:	
Prescriber Name:	Prescriber In		Fax:	
	Pho		rax:	
Address:	NPI			_
City, State: Zi	o: Offi	ce Contact:		
Fax completed form, insurance information, and clinical documentation to:				
CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that do not require authorization. You are obligated to maintain it in a safe, secure, and confidential manner, Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient				

CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that do not require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.